Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
HIV Med ; 21(11): 722-728, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-33369028

RESUMEN

OBJECTIVES: To describe the clinical characteristics and factors associated with CD4 T-cell count and CD4/CD8 ratio restoration in HIV mono-infected and HIV/HBV co-infected individuals, and to explore liver and renal functional changes in both groups. METHODS: A retrospective cohort study was performed including 356 HIV/HBV co-infected and 716 HIV mono-infected participants who initiated antiretroviral therapy (ART) during 2013-2017 in Beijing Youan Hospital, China. Demographic and clinical characteristics were compared between the two groups, using χ2 and Mann-Whitney non-parametric tests. Bivariate and multivariate Cox regression models were used to test their association. RESULTS: Baseline HIV viral load and ART regimen were found to be significantly associated with CD4 T-cell restoration among HIV-infected participants, whereas baseline HIV viral load was the only significant factor associated with CD4 T-cell restoration in HIV/HBV co-infected participants. The final model showed that baseline HIV viral load and ART regimen were significantly associated with CD4/CD8 ratio restoration among HIV-infected participants, while baseline HIV viral load was the significant factor. Liver and renal functions were similar at the endpoint (P > 0.05). CONCLUSIONS: Baseline HIV viral load count was found to be the key factor affecting immune restoration in both HIV and HIV/HBV individuals. Future multi-wave prospective studies are needed to clarify the potential biological mechanism.


Asunto(s)
Antirretrovirales/uso terapéutico , Coinfección/tratamiento farmacológico , Infecciones por VIH/tratamiento farmacológico , Hepatitis B/tratamiento farmacológico , Adulto , Recuento de Linfocito CD4 , Relación CD4-CD8 , China , Coinfección/inmunología , Femenino , Infecciones por VIH/inmunología , Hepatitis B/inmunología , Humanos , Reconstitución Inmune , Pruebas de Función Renal , Pruebas de Función Hepática , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Resultado del Tratamiento , Carga Viral , Adulto Joven
2.
Clin Transl Oncol ; 21(9): 1250-1259, 2019 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-30788837

RESUMEN

BACKGROUND: Angiogenesis is an indispensable step in the growth and invasiveness of breast cancers involving a series of exquisite molecular steps. Pro-angiogenic factors, including vascular endothelial growth factor (VEGF), have been recognized as pivotal therapeutic targets in the treatment of breast cancer. More recently, a highly conserved transcription factor Twist has been reported to be involved in tumor angiogenesis and metastasis. METHODS: The expression of VEGF-C and Twist was immunohistochemically determined in tissue samples of primary tumors from 408 patients undergoing curative surgical resection for breast cancer. The correlations of VEGF-C and Twist expressions with clinicopathologic parameters as well as survival outcomes were evaluated. RESULTS: Of the 408 patients evaluated, approximately 70% had high expression of VEGF-C which was significantly associated with advanced tumor stages (P = 0.019). Similarly, VEGF-C expression was associated with the proliferation index Ki67, N3 lymph node metastasis, and D2-40-positive lymphatic vessel invasion (LVI) in a univariate analysis. Furthermore, patients with high expressions of VEGF-C and Twist (V + T+) had significantly increased lymph node metastasis, higher clinical stage, and worse disease-free survival, DFS (P = 0.001) and overall survival, OS (P = 0.011). CONCLUSIONS: Our results suggested that co-expression of VEGF-C and Twist was associated with larger tumor size, higher numbers of lymph node involvement, D2-40-positive LVI, higher risk of distant metastasis, and worse DFS or OS in breast cancer patients.


Asunto(s)
Biomarcadores de Tumor/metabolismo , Neoplasias de la Mama/patología , Carcinoma Ductal de Mama/patología , Proteínas Nucleares/metabolismo , Proteína 1 Relacionada con Twist/metabolismo , Factor C de Crecimiento Endotelial Vascular/metabolismo , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/cirugía , Carcinoma Ductal de Mama/metabolismo , Carcinoma Ductal de Mama/cirugía , Femenino , Estudios de Seguimiento , Regulación Neoplásica de la Expresión Génica , Humanos , Persona de Mediana Edad , Pronóstico , Tasa de Supervivencia
3.
Drug Discov Ther ; 1(2): 86-8, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22504392

RESUMEN

To study the prevalence of drug resistance mutations among HAART (highly active anti-retroviral therapy) naive subjects with HIV-1 subtype B infection, evaluate the correlation between major mutations and viral loads. Additionally, to investigate the primary resistance spectrum in the central plains of China and provide some guidance for the choice of antiretroviral drugs (ARV). Drug resistance mutations and viral loads were measured in 78 treatment-naïve patients with HIV infection and the results were analyzed with descriptive statistical and multiple statistical analysis. The most common mutations were L63P, V77I and I93L, which belong to minor mutations of the proteinase gene, and none of which had any relation to viral loads. The major mutations, which were mainly K103N and Q151M, were less frequent in China than those in other countries. There was a certain correlation between viral loads and I93IL according to stepwise regression analysis. The incidence of primary mutations among HAART naïve patients was lower in China's central plains than that in other countries, and the most common mutations had no relation to viral loads. Though major mutations affecting choice of ARV are not common in China, they deserve further attention.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA